Statin use, incident dementia and Alzheimer disease in elderly African Americans

Hugh Hendrie, Ann Hake, Kathleen Lane, Christianna Purnell, Frederick Unverzagt, Valerie Smith-Gamble, Jill Murrell, Adesola Ogunniyi, Olusegun Baiyewu, Christopher Callahan, Andrew Saykin, Stanley Taylor, Kathleen Hall, Sujuan Gao

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort. Design: Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period. Diagnoses of incident AD and dementia were made by consensus. Statin use was collected at each evaluation. Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples. Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels. Setting: Indianapolis, Indiana Participants: From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included. Main Outcome Measures: Incident dementia and incident AD. Results: After controlling for age at diagnosis, sex, education level, presence of the APOE e4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.44, P=.029) and incident AD (OR=.40, P=.029). The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: P=.034; incident dementia: P=.061). Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD. Conclusions: Consistent use of statin medications during eight years of followup resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia.

Original languageEnglish (US)
Pages (from-to)345-354
Number of pages10
JournalEthnicity and Disease
Volume25
Issue number3
StatePublished - Jun 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
African Americans
Dementia
Alzheimer Disease
C-Reactive Protein
LDL Cholesterol
Logistic Models
Sex Education
Cognition
Consensus
Biomarkers
Stroke
Alleles
Genotype
Outcome Assessment (Health Care)
Interviews
Lipids

Keywords

  • African Americans
  • Alzheimer disease
  • Cohort studies
  • Dementia
  • Hydroxymethylglutaryl-CoA reductase inhibitors

ASJC Scopus subject areas

  • Epidemiology
  • Medicine(all)

Cite this

Statin use, incident dementia and Alzheimer disease in elderly African Americans. / Hendrie, Hugh; Hake, Ann; Lane, Kathleen; Purnell, Christianna; Unverzagt, Frederick; Smith-Gamble, Valerie; Murrell, Jill; Ogunniyi, Adesola; Baiyewu, Olusegun; Callahan, Christopher; Saykin, Andrew; Taylor, Stanley; Hall, Kathleen; Gao, Sujuan.

In: Ethnicity and Disease, Vol. 25, No. 3, 01.06.2015, p. 345-354.

Research output: Contribution to journalArticle

Hendrie, H, Hake, A, Lane, K, Purnell, C, Unverzagt, F, Smith-Gamble, V, Murrell, J, Ogunniyi, A, Baiyewu, O, Callahan, C, Saykin, A, Taylor, S, Hall, K & Gao, S 2015, 'Statin use, incident dementia and Alzheimer disease in elderly African Americans', Ethnicity and Disease, vol. 25, no. 3, pp. 345-354.
Hendrie, Hugh ; Hake, Ann ; Lane, Kathleen ; Purnell, Christianna ; Unverzagt, Frederick ; Smith-Gamble, Valerie ; Murrell, Jill ; Ogunniyi, Adesola ; Baiyewu, Olusegun ; Callahan, Christopher ; Saykin, Andrew ; Taylor, Stanley ; Hall, Kathleen ; Gao, Sujuan. / Statin use, incident dementia and Alzheimer disease in elderly African Americans. In: Ethnicity and Disease. 2015 ; Vol. 25, No. 3. pp. 345-354.
@article{5356656379154164bd4b1346fcd8804f,
title = "Statin use, incident dementia and Alzheimer disease in elderly African Americans",
abstract = "Objective: To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort. Design: Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period. Diagnoses of incident AD and dementia were made by consensus. Statin use was collected at each evaluation. Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples. Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels. Setting: Indianapolis, Indiana Participants: From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included. Main Outcome Measures: Incident dementia and incident AD. Results: After controlling for age at diagnosis, sex, education level, presence of the APOE e4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.44, P=.029) and incident AD (OR=.40, P=.029). The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: P=.034; incident dementia: P=.061). Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD. Conclusions: Consistent use of statin medications during eight years of followup resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia.",
keywords = "African Americans, Alzheimer disease, Cohort studies, Dementia, Hydroxymethylglutaryl-CoA reductase inhibitors",
author = "Hugh Hendrie and Ann Hake and Kathleen Lane and Christianna Purnell and Frederick Unverzagt and Valerie Smith-Gamble and Jill Murrell and Adesola Ogunniyi and Olusegun Baiyewu and Christopher Callahan and Andrew Saykin and Stanley Taylor and Kathleen Hall and Sujuan Gao",
year = "2015",
month = "6",
day = "1",
language = "English (US)",
volume = "25",
pages = "345--354",
journal = "Ethnicity and Disease",
issn = "1049-510X",
publisher = "ISHIB",
number = "3",

}

TY - JOUR

T1 - Statin use, incident dementia and Alzheimer disease in elderly African Americans

AU - Hendrie, Hugh

AU - Hake, Ann

AU - Lane, Kathleen

AU - Purnell, Christianna

AU - Unverzagt, Frederick

AU - Smith-Gamble, Valerie

AU - Murrell, Jill

AU - Ogunniyi, Adesola

AU - Baiyewu, Olusegun

AU - Callahan, Christopher

AU - Saykin, Andrew

AU - Taylor, Stanley

AU - Hall, Kathleen

AU - Gao, Sujuan

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective: To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort. Design: Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period. Diagnoses of incident AD and dementia were made by consensus. Statin use was collected at each evaluation. Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples. Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels. Setting: Indianapolis, Indiana Participants: From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included. Main Outcome Measures: Incident dementia and incident AD. Results: After controlling for age at diagnosis, sex, education level, presence of the APOE e4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.44, P=.029) and incident AD (OR=.40, P=.029). The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: P=.034; incident dementia: P=.061). Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD. Conclusions: Consistent use of statin medications during eight years of followup resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia.

AB - Objective: To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort. Design: Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period. Diagnoses of incident AD and dementia were made by consensus. Statin use was collected at each evaluation. Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples. Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels. Setting: Indianapolis, Indiana Participants: From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included. Main Outcome Measures: Incident dementia and incident AD. Results: After controlling for age at diagnosis, sex, education level, presence of the APOE e4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.44, P=.029) and incident AD (OR=.40, P=.029). The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: P=.034; incident dementia: P=.061). Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD. Conclusions: Consistent use of statin medications during eight years of followup resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia.

KW - African Americans

KW - Alzheimer disease

KW - Cohort studies

KW - Dementia

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84962544264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962544264&partnerID=8YFLogxK

M3 - Article

C2 - 26673814

AN - SCOPUS:84962544264

VL - 25

SP - 345

EP - 354

JO - Ethnicity and Disease

JF - Ethnicity and Disease

SN - 1049-510X

IS - 3

ER -